RESUMEN
BACKGROUND: Therapeutic drug monitoring (TDM) contributes to optimizing exposure to ß-lactam antibiotics. However, how excessive exposure to ß-lactams can increase the burden of care of critically ill patients is unclear. PATIENTS AND METHODS: In a prospective cohort study, we examined whether excessive ß-lactam serum concentrations contribute to neurological deterioration and the associated complications of adult septic patients without recent history of neurological disease treated with ß-lactams in a medical ICU. Excessive ß-lactam concentrations were defined as serum concentrations that exceeded the upper limit of the therapeutic range recommended by the French Societies of Pharmacology and Therapeutics (SFPT) and Anesthesia and Intensive Care Medicine (SFAR). Neurological deterioration was defined as an increase in the neurological Sequential Organ Failure Assessment score (nSOFA) of ≥1 between the day of starting treatment at admission and the day of TDM performed 2 days after treatment initiation. RESULTS: We included 119 patients [median age: 65 years; males: 78 (65.5%)] admitted for acute respiratory distress [59 (49.6%)] or septic shock [25 (21%)]. In adjusted logistic regression analysis, an excessive ß-lactam serum concentration was associated with neurological deterioration [OR (95% CI): 10.38 (3.23-33.35), Pâ<â0.0001]. Furthermore, in adjusted linear regression analysis, an excessive ß-lactam serum concentration was associated with longer time to discharge alive (ß=0.346, Pâ=â0.0007) and, among mechanically ventilated patients discharged alive, with longer time to extubation following the withdrawal of sedation (ß=0.248, Pâ=â0.0030). CONCLUSIONS: These results suggest that excessive exposure to ß-lactams could complicate the management of septic patients in the ICU and confirm the clinical relevance of the upper concentration limits recommended for dose reduction.
Asunto(s)
Choque Séptico , beta-Lactamas , Masculino , Adulto , Humanos , Anciano , Antibacterianos/farmacología , Estudios Prospectivos , Enfermedad Crítica/terapia , Choque Séptico/tratamiento farmacológicoRESUMEN
BACKGROUND: The uraemic toxins that accumulate as renal function deteriorates can potentially affect drug pharmacokinetics. This study's objective was to determine whether plasma concentrations of certain uraemic toxins are correlated with blood concentrations of two immunosuppressants. METHODS: DRUGTOX was a cross-sectional study of 403 adult patients followed up after kidney transplantation and who had undergone therapeutic drug monitoring (TDM) of calcineurin inhibitors (tacrolimus or cyclosporin) between August 2019 and March 2020. For each patient, immunosuppressant trough concentrations (C0) were measured in whole blood samples and then normalized against the total daily dose (C0:D ratio). The sample was assayed for five uraemic toxins [urea, trimethylamine N-oxide (TMAO), indole acetic acid (IAA), p-cresylsulphate (PCS) and indoxylsulphate (IxS)] using liquid chromatography-tandem mass spectrometry. RESULTS: The median age was 56 years [interquartile range (IQR) 48-66] and the median estimated glomerular filtration rate was 41 mL/min/1.73 m2 (IQR 30-57). Age, sex, body mass index (BMI), urea, IxS and PCS were significantly associated with an increment in the tacrolimus C0:D ratio. A multivariate analysis revealed an independent association with IxS [odds ratio 1.36 (95% confidence interval 1.00-1.85)] after adjustment for sex, age and BMI, whereas adjustment for age weakened the association for PCS and urea. In a univariate logistic analysis, age, sex, BMI and the TMAO level (but not PCS, IxS, IAA or urea) were significantly associated with an increment in the cyclosporine C0:D ratio. CONCLUSIONS: Even though TDM and dose adaptation of immunosuppressants keep levels within the therapeutic window, increased exposure to tacrolimus (but not cyclosporine) is associated with an accumulation of PCS, IxS and urea.
Asunto(s)
Inhibidores de la Calcineurina , Trasplante de Riñón , Humanos , Persona de Mediana Edad , Inhibidores de la Calcineurina/uso terapéutico , Estudios Transversales , Ciclosporina/uso terapéutico , Inmunosupresores , Tacrolimus/uso terapéutico , Receptores de Trasplantes , Urea , Tóxinas Urémicas , AncianoRESUMEN
It is not known whether the adverse events (AEs) associated with the administration of lopinavir and ritonavir (LPV/r) in the treatment of COVID-19 are concentration-dependent. In a retrospective study of 65 patients treated with LPV/r and therapeutic drug monitoring (TDM) for severe forms of COVID-19 (median age: 67; males: 41 [63.1%]), 33 (50.8%) displayed a grade ≥2 increase in plasma levels of hepatobiliary markers, lipase and/or triglycerides. A causal relationship between LPV/r and the AE was suspected in 9 of the 65 patients (13.8%). At 400 mg b.i.d., the plasma trough concentrations of LPV/r were high and showed marked interindividual variability (median [interquartile range]: 16,600 [11,430-20,842] ng/ml for lopinavir and 501 [247-891] ng/ml for ritonavir). The trough lopinavir concentration was negatively correlated with body mass index, while the trough ritonavir concentration was positively correlated with age and negatively correlated with prothrombin activity. However, the occurrence of abnormal laboratory values was not associated with higher trough plasma concentrations of LPV/r. Further studies will be needed to determine the value of TDM in LPV/r-treated patients with COVID-19.
Asunto(s)
Antirretrovirales/efectos adversos , Antirretrovirales/sangre , COVID-19/sangre , Lopinavir/efectos adversos , Lopinavir/sangre , Ritonavir/efectos adversos , Ritonavir/sangre , Anciano , Anciano de 80 o más Años , Envejecimiento/metabolismo , Antirretrovirales/uso terapéutico , Índice de Masa Corporal , Femenino , Humanos , Lopinavir/uso terapéutico , Masculino , Persona de Mediana Edad , Protrombina/análisis , Estudios Retrospectivos , Ritonavir/uso terapéutico , Tratamiento Farmacológico de COVID-19RESUMEN
OBJECTIVES: To determine the plasma metformin concentration threshold associated with lactic acidosis and analyze the outcome in metformin-treated patients with lactic acidosis hospitalized in an emergency context. DESIGN: A retrospective, observational, single-center study. SETTING: Emergency department and ICUs at Amiens University Hospital (Amiens, France). PATIENTS: All consecutive patients with data on arterial lactate and pH up to 12 hours before or after a plasma metformin assay within 24 hours of admission, over a 9.7-year period. INTERVENTION: None. MEASUREMENTS AND MAIN RESULTS: The study population consisted of 194 metformin-treated diabetic patients (median age: 68.6; males: 113 [58.2%]); 163 (84%) had acute kidney injury, which was associated variously with dehydration (45.4%), sepsis (41.1%), cardiogenic shock (20.9%), and diabetic ketoacidosis (16%). Eighty-seven patients (44.8%) had lactic acidosis defined as an arterial blood pH less than 7.35 and a lactate concentration greater than or equal to 4 mM, and 38 of them (43.7%) died in the ICU. A receiver operating characteristic curve analysis showed that a metformin concentration threshold of 9.9 mg/L was significantly associated with the occurrence of lactic acidosis (specificity: 92.9%; sensitivity: 67.1%; area under the receiver operating characteristic curve: 0.83; p < 0.0001). Among lactic acidosis-positive patients, however, in-ICU death was less frequent when the metformin concentration was greater than or equal to 9.9 mg/L (33.9% vs 61.3% for < 9.9 mg/L; p = 0.0252). After adjustment for the Simplified Acute Physiology Score II, in-ICU death was positively associated with prothrombin activity less than 70% and negatively associated with the initiation of renal replacement therapy at admission. CONCLUSIONS: In metformin-treated patients admitted in an emergency context, a plasma metformin concentration greater than or equal to 9.9 mg/L was strongly associated with the presence of lactic acidosis. This threshold may assist with the delicate decision of whether or not to initiate renal replacement therapy. Indeed, the outcome of lactic acidosis might depend on the prompt initiation of renal replacement therapy-especially when liver failure reduces lactate elimination.
Asunto(s)
Acidosis Láctica/mortalidad , Metformina/sangre , Acidosis Láctica/sangre , Acidosis Láctica/inducido químicamente , Anciano , Servicio de Urgencia en Hospital/estadística & datos numéricos , Femenino , Mortalidad Hospitalaria , Humanos , Unidades de Cuidados Intensivos/estadística & datos numéricos , Masculino , Metformina/efectos adversos , Persona de Mediana Edad , Estudios Retrospectivos , Factores de RiesgoRESUMEN
It is difficult to carry out toxicological investigations in biological samples collected from extensively decomposed bodies and to interpret obtained results as several pitfalls should be considered: redistribution phenomena, degradation of xenobiotics during the postmortem period, contamination by putrefaction fluids, and external contamination. This work aims to present two cases in order to illustrate and discuss these difficulties in this tricky situation. Case#1: the body of a 30-year-old woman was found in a wooded area (1 month after she has been reported missing by her family): hair and a femur section were sampled. Case#2: the decomposed corpse of a 52-year-old man was found in a ditch: hair and nails were sampled. After decontamination steps, toxicological investigations were performed using liquid chromatography with high-resolution mass spectrometry and tandem mass spectrometry detection methods. In case#1, the same drugs or metabolites (benzodiazepines, propranolol, tramadol, acetaminophen, paroxetine, and oxetorone) were detected in hair and in bone specimens. This result combination strongly suggests intakes close to the time of death for three of them (oxazepam, lormetazepam, and propranolol). In case#2, results of toxicological investigations in hair and nails [(hair/nail concentration in ng/mg) nordiazepam (1.12/1.06), oxazepam (0.113/0.042), zolpidem (0.211/< 0.01), hydroxyzine (0.362/< 0.01), and cetirizine (0.872/1.110)] were both consistent with several drug intakes but were not contributory to cause of death determination. In case of positive toxicological results in biological samples collected from extensively decomposed bodies (such as hair, bones, or nails), it is challenging to determine the time, and even more, the level of the dose of exposure(s).
Asunto(s)
Restos Mortales , Toxicología Forense , Cambios Post Mortem , Detección de Abuso de Sustancias/métodos , Adulto , Benzodiazepinas/análisis , Huesos/química , Femenino , Cabello/química , Humanos , Hidroxizina/análisis , Masculino , Persona de Mediana Edad , Uñas/química , Propranolol/análisis , Manejo de Especímenes , Zolpidem/análisisRESUMEN
Ceftobiprole is a fifth-generation cephalosporin approved for the treatment of pneumonia, with a broad antibacterial spectrum, including potent activity against methicillin-resistant Staphylococcus aureus As for the other cephalosporins, high pharmacokinetic variability and concentration-dependent neurotoxicity are expected. We describe here the first simple and rapid analytical method intended for ceftobiprole serum concentration monitoring. We report the data of 5 patients treated with ceftobiprole, among who 2 developed reversible neurological disorders with high ceftobiprole serum concentration.
Asunto(s)
Antibacterianos/sangre , Cefalosporinas/sangre , Cromatografía Líquida de Alta Presión/métodos , Monitoreo de Drogas/métodos , Anciano , Antibacterianos/efectos adversos , Calibración , Cefalosporinas/efectos adversos , Femenino , Humanos , Masculino , Convulsiones/inducido químicamenteRESUMEN
OBJECTIVE: To determine whether perinatal smoking exposure is associated with gastroesophageal reflux (GER)-related changes in sleep-wakefulness states in neonates. STUDY DESIGN: Thirty-one neonates, referred for the investigation of suspected GER, were recruited and underwent multichannel impedance-pH monitoring and synchronized 8- to 12-hour polysomnography. The infants' exposure to tobacco smoke was estimated by means of a urine cotinine assay. The total number, frequency (h-1), and mean duration (minutes) of GER-pH (reflux events detected by the pH electrode only) and GER-imp (reflux events with bolus movement detected by impedance) events were determined. Intergroup differences (smoking-exposed group vs nonexposed group) were probed with nonparametric, unpaired Mann-Whitney U tests. A χ2 test was used to assess a possible intergroup difference in bolus retrograde migration during GER-imp events. RESULTS: According to the urine cotinine assay, 21 of the 31 neonates had been exposed to cigarette smoke during the perinatal period. The number (and frequency) of GER-imp was significantly greater (P = .016) in the exposed group (29 [0-90]) than in the nonexposed group (12 [2-35]). Migration of the esophageal bolus from the distal segment to the most proximal segment was significantly more frequent (P = .016) in the exposed group (83% of GER) than in the nonexposed group (41%). The GER pattern associated with smoking exposure was particularly obvious during Rapid eye movement sleep. CONCLUSIONS: The more frequent occurrence and greater proximal migration of GER-imp in the smoking-exposed group (especially during rapid eye movement sleep) may have clinical relevance. Smoking exposure is a preventable risk factor for limiting the occurrence of GER in neonates.
Asunto(s)
Esófago/fisiopatología , Reflujo Gastroesofágico/fisiopatología , Exposición Materna/efectos adversos , Sueño/fisiología , Fumar/efectos adversos , Vigilia/fisiología , Impedancia Eléctrica , Esófago/metabolismo , Femenino , Reflujo Gastroesofágico/metabolismo , Humanos , Concentración de Iones de Hidrógeno , Recién Nacido , Masculino , PolisomnografíaRESUMEN
This retrospective cohort study included 53 patients admitted to the intensive care unit (ICU), with an average age of 69 years, without neurologic disorder before initiation of a continuous piperacillin infusion at the standard dose and who underwent piperacillin serum concentration monitoring. Among them, 23 developed a neurologic disorder for which the piperacillin causality was chronologically and semiologically suggestive. A concentration threshold of 157.2 mg/liter independently predicted neurotoxicity with 96.7% specificity and 52.2% sensitivity and may constitute a limitation when targeting less susceptible pathogens.
Asunto(s)
Antibacterianos/toxicidad , Antibacterianos/uso terapéutico , Enfermedades del Sistema Nervioso/inducido químicamente , Piperacilina/toxicidad , Piperacilina/uso terapéutico , Anciano , Antibacterianos/administración & dosificación , Cuidados Críticos/métodos , Enfermedad Crítica , Monitoreo de Drogas , Enterobacteriaceae/efectos de los fármacos , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Infecciones por Enterobacteriaceae/microbiología , Femenino , Humanos , Infusiones Intraarteriales , Masculino , Persona de Mediana Edad , Ácido Penicilánico/análogos & derivados , Ácido Penicilánico/uso terapéutico , Piperacilina/administración & dosificación , Estudios Retrospectivos , TazobactamRESUMEN
BACKGROUND: Nicotinamide (NAM) has been proposed as an alternative treatment to phosphate binders for hyperphosphataemia in chronic kidney disease. METHODS: The NICOREN multicentre, open-label and randomized study was designed to examine non-inferiority and safety of NAM when compared with sevelamer (SEV) in chronic haemodialysis patients. One hundred patients were randomized to either NAM or SEV treatment for 24 weeks. Serum biochemistry and NAM's main metabolite, N -methyl-2-pyridone-5-carboxamide (2PY), were measured to assess compliance, efficacy and safety. RESULTS: After 24 weeks, we observed a comparable decrease in serum phosphorus in the NAM and SEV treatment arms, from 2.1 ± 0.4 to 1.8 ± 0.5 and 2.3 ± 0.5 to 1.7 ± 0.5 mM (P = not significant), respectively. The criterion for non-inferiority was, however, not met due to a more limited number of patients being included than planned. Treatment discontinuation due to adverse events was 1.6 times higher in the NAM than in the SEV group with only 55% of study completers in the NAM arm versus 90% in the SEV arm. Thrombocytopenia was observed in four NAM-treated patients. Serum 2PY levels were comparable at baseline, but increased markedly in the NAM group, but not in the SEV group, at 24 weeks (P < 0.0001). CONCLUSIONS: Thus, both drugs are equally effective in lowering serum phosphorus, but patients' tolerance of NAM was largely inferior to that of SEV. Extremely high 2PY levels may contribute to NAM's side effects.
Asunto(s)
Hiperfosfatemia/tratamiento farmacológico , Niacinamida/administración & dosificación , Fósforo/sangre , Diálisis Renal , Insuficiencia Renal Crónica/complicaciones , Sevelamer/administración & dosificación , Adulto , Anciano , Femenino , Humanos , Hiperfosfatemia/etiología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Insuficiencia Renal Crónica/terapiaRESUMEN
BACKGROUND: The optimization of combination therapy with ribavirin (RBV) and pegylated interferon alpha has substantially improved sustained virologic response (SVR) rates and lowered virologic relapse rates in patients infected with hepatitis C virus (HCV). In this study, we performed an analysis of the relationship between the end-of-treatment plasma RBV concentration and virologic relapse. METHODS: Thirty-four patients with HCV treated with pegylated interferon/RBV and with an end-of-treatment response were assayed for plasma RBV concentration using liquid chromatography assay coupled to tandem mass-spectrometric detection on the last day of the treatment. Clinical data and the concentration of RBV were compared between patients classified as either relapsers or nonrelapsers. RESULTS: Eleven patients (32.4%) relapsed and 23 patients (67.6%) achieved an SVR. The mean plasma RBV concentration on the last day of treatment was 1380 ± 312 ng/mL for relapsers and 2278 ± 569 ng/mL for SVR patients (P < 0.0001). A receiver operating characteristic analysis showed that a threshold of 1960 ng/mL was associated with the greatest sensitivity and specificity (100% and 83%, respectively, with an area under the curve of 0.94; P < 0.0001) for discriminating between patients who relapsed and those who did not. A univariate logistic regression analysis indicated that a plasma RBV concentration of <1960 ng/mL at the end of the treatment was strongly associated with relapse (odds ratio, 55; 95% confidence interval, 7.24-∞; P = 0.0001) independently of age, body weight, RBV dose, baseline viral load, the interleukin-28B genotype, and response to previous courses of treatment. CONCLUSIONS: Our study results highlight the relevance of measuring plasma RBV concentrations during and at the end of HCV treatment, with a view to avoiding virologic relapse.
Asunto(s)
Antivirales/sangre , Cromatografía Liquida/métodos , Hepatitis C Crónica/tratamiento farmacológico , Ribavirina/sangre , Adulto , Antivirales/administración & dosificación , Antivirales/uso terapéutico , Área Bajo la Curva , Quimioterapia Combinada , Femenino , Humanos , Interferón alfa-2 , Interferón-alfa/administración & dosificación , Interferón-alfa/uso terapéutico , Modelos Logísticos , Masculino , Persona de Mediana Edad , Polietilenglicoles/administración & dosificación , Polietilenglicoles/uso terapéutico , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/uso terapéutico , Recurrencia , Estudios Retrospectivos , Ribavirina/administración & dosificación , Ribavirina/uso terapéutico , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem/métodos , Factores de Tiempo , Resultado del TratamientoAsunto(s)
Antifúngicos/metabolismo , Antifúngicos/farmacocinética , Aspergilosis/tratamiento farmacológico , Aspergilosis/genética , Citocromo P-450 CYP2C19/genética , Voriconazol/metabolismo , Voriconazol/farmacocinética , Adulto , Antifúngicos/sangre , Aspergilosis/metabolismo , Femenino , Genotipo , Homocigoto , Humanos , Oxidación-Reducción , Insuficiencia del Tratamiento , Voriconazol/sangreRESUMEN
The potential neurotoxicity of betalactam antibiotics are well-known and is frequently associated with drug accumulation in patients with renal failure since these antibiotics are eliminated mostly by kidneys. The regional center of pharmacovigilance of Amiens has collected since 10 years, 20 notifications of neurotoxicity induced by betalactam antibiotics. The series included eight women and 12 men. Mean age was 65 years (26-84). The drug accumulation hypothesis was strengthened in nine cases by assays of plasma levels residual concentrations. In 17 cases, betalactam antibiotics dosage was adapted to creatinin clearance in accordance to the Summary of the Product Characteristics' (SPC) recommendations. For several drugs, no adaptation to renal function was proposed by SPC. Dosage adaptation based only on renal function as it's recommended is not always efficient to avoid neurological side effects.
Asunto(s)
Antibacterianos/efectos adversos , Epilepsia/inducido químicamente , Tasa de Depuración Metabólica , Guías de Práctica Clínica como Asunto , beta-Lactamas/efectos adversos , Adulto , Anciano , Anciano de 80 o más Años , Antibacterianos/administración & dosificación , Antibacterianos/farmacocinética , Creatinina/sangre , Relación Dosis-Respuesta a Droga , Epilepsia/epidemiología , Femenino , Francia/epidemiología , Antagonistas del GABA/efectos adversos , Humanos , Enfermedades Renales/complicaciones , Enfermedades Renales/metabolismo , Enfermedades Renales/fisiopatología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , beta-Lactamas/administración & dosificación , beta-Lactamas/farmacocinéticaAsunto(s)
4-Aminopiridina/análogos & derivados , Botulismo/diagnóstico , Botulismo/tratamiento farmacológico , Bloqueo Neuromuscular/métodos , 4-Aminopiridina/administración & dosificación , Potenciales de Acción/efectos de los fármacos , Potenciales de Acción/fisiología , Adulto , Amifampridina , Botulismo/fisiopatología , Femenino , Humanos , Proyectos Piloto , Adulto JovenRESUMEN
A novel method based upon liquid chromatography coupled to ion trap mass spectrometry (MS) detection with electrospray ionization interface has been developed for the identification and quantification of colchicine in plasma or whole blood. Colchicine was isolated from plasma using a liquid-liquid extraction with dichloromethane at pH 8.0 and embutramide as an internal standard, with satisfactory extraction recoveries. Solutes were separated on a 3-microm C18 Uptisphere (Interchim) column (150 x 2.0-mm i.d.) using acetonitrile/2 mM NH4COOH pH 3.8 buffer (50:50, v/v) as the mobile phase with a flow-rate of 200 microL/min. Data were collected either in full-scan MS mode at m/z 100-450 or in full-scan MS-MS mode, selecting the ion m/z 400.1 for colchicine and m/z 294.1 for embutramide. The most intense daughter ion of colchicine (m/z 358.1) and embutramide (m/z 207.9) were used for quantification. Retention times were 2.40 and 4.25 min for colchicine and embutramide, respectively. Calibration curves were linear in the 0.50-50 ng/mL range. The limits of detection and quantification were 0.05 ng/mL and 0.50 ng/mL, respectively. The intra- and interassay precisions were < 14%, and the intra- and interassay accuracies were in the 97-105.8% range at either 2 or 20 ng/mL. A fatal case of colchicine self-poisoning with a lethal blood concentration of 60 ng/mL and nonfatal case with a plasma sample collected very late (at least 36 h after the ingestion) are presented. The described method enables the unambiguous identification and quantification of colchicine with a very good sensitivity, using only 1 mL of sample.
Asunto(s)
Colchicina/sangre , Adulto , Anciano , Cromatografía Liquida/métodos , Colchicina/envenenamiento , Femenino , Humanos , Masculino , Reproducibilidad de los Resultados , Sensibilidad y Especificidad , Espectrometría de Masa por Ionización de Electrospray/métodosRESUMEN
N-methyl-2-pyridone-5-carboxamide (2PY, a major metabolite of nicotinamide, NAM) was recently identified as a uremic toxin. Recent interventional trials using NAM to treat high levels of phosphorus in end-stage renal disease have highlighted new potential uremic toxicities of 2PY. In the context of uremia, the accumulation of 2PY could be harmful-perhaps by inhibiting poly (ADP-ribose) polymerase-1 activity. Here, we review recently published data on 2PY's metabolism and toxicological profile.
Asunto(s)
Niacinamida/análogos & derivados , Niacinamida/metabolismo , Toxinas Biológicas/metabolismo , Uremia/metabolismo , Animales , Humanos , Insuficiencia Renal Crónica/metabolismoRESUMEN
The activity of the osteoclast, the cell responsible for bone resorption, is subjected to different regulation factors. Amongst these, those issued from the matrix, particularly released minerals such as calcium, are determinants. We have shown that variations in calcium concentration in the medium regulates resorption activity and duration of the osteoclast lifespan. The development of a new therapeutic agent, strontium ranelate, has shown very interesting clinical effects reliant on the stimulation of bone formation activity by osteoblasts and modulation of bone resorption activity. From our knowledge regarding osteoclast physiology, in particular calcium signaling pathways, and the control of different osteoclast cellular models, a consequent collaboration was formed between our laboratory and Servier in order to elaborate on the effects of strontium ranelate on the osteoclast. In several years, this collaboration has been further enriched by other collaborators in order to better understand this mechanism. It has also been shown that strontium likely interacts with the calcium-sensing receptor and that the pathways of intracellular signaling pathways activated by calcium and strontium ranelate via this receptor are different. In fact, within the scope of this collaboration with Servier, exchanges with other academic laboratories were initiated and collaboration on numerous techniques became possible. Then, it has been possible to confirm the presence of the calcium-sensing receptor on the osteoclasts and to demonstrate its role in the molecular events associated with strontium ranelate's effects on the osteoclast.